Baltimore, MD – July 22, 2015 – WellDoc®, a leading expert in mobile health innovation, announced its participation in the Mobile and Personal Technologies in Precision Medicine event, which will be hosted by the Precision Medicine Initiative (PMI) Working Group of the Advisory Committee to the NIH Director (ACD). The session will be webcast live on July 27 from 11:00 a.m.-8:00 p.m. EST and July 28 from 11:00 a.m.-3:15 p.m. EST, and held at the Intel Corporation campus in Santa Clara, California (to sign up please visit the NIH website).
Building on President Obama’s announcement in his State of the Union Address, the Precision Medicine Initiative is a bold research effort to revolutionize how to improve health and treat disease. Launched with a $215 million investment in the President’s 2016 Budget, the Precision Medicine Initiative will pioneer a new model of patientpowered research that promises to accelerate biomedical discoveries and provide clinicians with new tools, knowledge, and therapies to select treatments that are better targeted for different types of patients.
Part of advancing precision medicine is incorporating personalized mobile technologies that guide the patient to improve outcomes and change behavior.
“WellDoc is proud to be a part of the dialogue to improve health outcomes through precision medicine and to support the administration’s critical initiative,” says Dr. Anand K. Iyer, Chief Data Science Officer at WellDoc. “We are committed to helping the government and the broader healthcare industry explore how we can improve the lives of patients through public-private partnership and on-going research.”
WellDoc has also played an important role with the International Medical Device Regulators Forum (IMDRF), in the creation of a global guidance document to address the unique needs of SaMD – Software as a Medical Device. WellDoc, along with the U.S. Food & Drug Administration (FDA), Health Canada, and several health authorities and leaders from around the globe, are finalizing this landmark guidance document after a series of workshops in Canada, Sweden and, soon to be, Brazil. “As one of the first companies to obtain FDA clearance for a clinically validated mobile app, the WellDoc team is proud to support and contribute to IMDRF. We are working with international medical device stakeholders to help align in what is needed for SaMD,” says Iyer.
For more information and the scientific justification of the Precision Medicine Initiative, see a related piece: a New England Journal of Medicine Perspective by NIH Director Dr. Francis S. Collins and former NCI Director Dr. Harold Varmus.
WellDoc is a digital health technology company that develops mobile solutions to drive behavioral and clinical change in chronic disease. WellDoc’s goal is to improve patient self-management and help physicians overcome gaps in the delivery system to improve clinical outcomes and decrease cost. WellDoc has commercialized the first mobile prescription therapy, BlueStar®, for adults with type 2 diabetes. Mobile prescription therapy fills the support gap between patients and providers during the 8700 hours that individuals are living their lives outside the healthcare system. WellDoc has a proven track record of contributing published, peer-reviewed clinical evidence since 2008 and as recently as June 2015 has presented real-world patient engagement and clinical outcomes at the American Diabetes Association’s (ADA) 75th Scientific Session. BlueStar is recognized by the ADA on its website as the first and only in a new class of diabetes treatment known as mobile prescription therapy (MPT). For more information, visit www.WellDoc.com and www.BlueStarDiabetes.com.